bioAffinity Technologies Inc.

BIAF | NASDAQ

Price Alert Chart Builder DCF Calculator

$8.80

+$1.10 (+14.29%)

Sep 22, 2026, 2:18 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+14.29%

(1D)

Rating

Updated: Aug 26, 2026

29.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $3.69M

1D Range

8.26 9.14

52W Range

4.56 109.35

Valuation (TTM)

PE -0.06

PB 0.86

EV/EBITDA -0.15

Valuation (NTM)

Forward PE N/A

Forward PEG 0.00

Price Target N/A

Cash Flow

FCF Yield -356.5%

SBC Adj. FCF Yield -364.6%

SBC Impact -2.3%

Margins

Gross Margin -39.6%

Operating Margin -209.8%

FCF Margin -194.9%

Growth (CAGR)

Revenue 3Y | 5Y 525.1% | 46.5%

Dil EPS 3Y | 5Y 51.7% | 50.5%

FCF 3Y | 5Y -25.2% | -28.6%

Returns

ROA -199.3%

ROE -257.3%

ROIC -237.9%

Financial Health

Net Cash

$2.13M

Current Ratio 1.44

Interest Coverage -276.15

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lun...

Sector Healthcare

Industry Medical - Diagnostics & Research

Employees 57

IPO Date Aug 31, 2022

Website www.bioaffinitytech.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 18, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞